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Spinocerebellar ataxia type 31 (SCA31) is an adult-onset autosomal-dominant neurodegenerative disorder showing progressive cere-
bellar ataxia mainly affecting Purkinje cells. The SCA31 critical region was tracked down to a 900 kb interval in chromosome
16q22.1, where the disease shows a strong founder effect. By performing comprehensive Southern blot analysis and BAC- and fos-
mid-based sequencing, we isolated two genetic changes segregating with SCA31. One was a single-nucleotide change in an intron of
the thymidine kinase 2 gene (TK2). However, this did not appear to affect splicing or expression patterns. The other was an insertion,
from 2.5–3.8 kb long, consisting of complex penta-nucleotide repeats including a long (TGGAA)n stretch. In controls, shorter (1.5–
2.0 kb) insertions lacking (TGGAA)n were found only rarely. The SCA31 repeat insertion’s length inversely correlated with patient
age of onset, and an expansion was documented in a single family showing anticipation. The repeat insertion was located in introns
of TK2 and BEAN (brain expressed, associated with Nedd4) expressed in the brain and formed RNA foci in the nuclei of patients’ Purkinje
cells. An electrophoreticmobility-shift assay showed that essential splicing factors, serine/arginine-rich splicing factors SFRS1 and SFRS9,
bind to (UGGAA)n in vitro. Because (TGGAA)n is a characteristic sequence of paracentromeric heterochromatin, we speculate that
the insertion might have originated from heterochromatin. SCA31 is important because it exempliﬁes human diseases associated
with ‘‘inserted’’ microsatellite repeats that can expand through transmission. Our ﬁnding suggests that the ectopic microsatellite repeat,
when transcribed, might cause a disease involving the essential splicing factors.Introduction
Autosomal-dominant cerebellar degenerative disorders are
generally referred to as spinocerebellar ataxia (SCA).1 Clin-
ically, progressive cerebellar ataxia is the cardinal neurolog-
ical symptom, and it is often accompanied by variable
extracerebellar neurological features, such as pyramidal
tract signs, extrapyramidal signs, ophthalmoparesis, and
sensory disturbances. Neuropathologically, the cerebellum
and its related systems, such as the brainstem, spinal cord,
and basal ganglia, can be involved to various degrees.
Nearly 30 genetic loci have been identiﬁed. Of
these, expansions of tri-nucleotide (CAG) repeats are the
causes of SCA1 (MIM #164400); SCA2 (MIM #183090);
SCA3, or Machado-Joseph disease (MJD) (MIM #109150);
SCA6 (MIM #183086), SCA7 (MIM #164500); SCA17
(MIM #607136); and dentatorubral-pallidoluysian atrophy544 The American Journal of Human Genetics 85, 544–557, Novem(DRPLA) (MIM #125370). These disorders, together with
Huntington disease (HD) (MIM þ143100) and spinal and
bulbar muscular atrophy (MIM #313200), are called
polyglutamine diseases2 because the CAG repeats, which
are expanded in patients, reside in the coding regions
and are translated into polyglutamine tracts. SCA8
(MIM #608768), SCA10 (MIM #603516), and SCA12
(MIM #604326) are caused by expansions of bidirection-
ally transcribed CTG and CAG; ATTCT; and CAG repeats,
respectively, in the non-coding regions of the responsible
genes. These disorders, together with myotonic dystrophy
type 1 (DM1) (MIM #160900), DM2 (MIM #602668), HD-
like disease type 2 (HDL2) (MIM #606438), and Fragile X
tremor/ataxia syndrome (FXTAS) (MIM #300623), caused
by RNA-mediated gain-of-function mechanisms, are called
noncoding repeat expansion disorders3. These are
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SCA are caused by static mutations (e.g., missense, frame-
shift, or deletion) in functionally important genes,4 such
as b-III spectrin (SPTBN2) (MIM #604985) in SCA5 (MIM
#600224), tau tubulin kinase 2 (TTBK2) (MIM #611695)
in SCA11 (MIM #604432), voltage-gated potassium
channel (KCNC3) (MIM #176264) in SCA13 (MIM
#605259), protein kinase C g (PRKCG) (MIM #176980)
for SCA14 (MIM #605361), inositol 1,4,5-triphosphate
receptor type 1 (ITPR1) (MIM #147265) in SCA15 (MIM
#606658), and ﬁbroblast growth factor 14 (FGF14) (MIM
#601515) in SCA27 (MIM #609307). The fact that so
many mutations result in the SCA phenotype in humans
suggests that the cerebellum and its related nervous
systems have particularly sophisticated and vulnerable
neurobiological characteristics.
We previously mapped a form of SCA (previously called
‘‘chromosome 16q22.1-linked autosomal dominant cere-
bellar ataxia [ADCA]’’; MIM #117210 and newly termed
as ‘‘SCA31’’ in this report) to human chromosome
16q22.1.5,6 This locus was already known for a clinically
distinct ataxia, SCA47 (MIM %600223). SCA31 presents
as pure cerebellar ataxia with an average age of onset of
61.2 years and thus is the latest to appear of all SCAs.6,8
The Purkinje cell, the only projecting neuron in the cere-
bellar cortex, is predominantly affected.8 SCA31 is esti-
mated to rank as the third most frequent SCA in Japan,
after SCA3 (MJD) and SCA6. In SCA4, in contrast, cere-
bellar ataxia is always accompanied by both sensory
axonal neuropathy and reduced or absent tendon reﬂexes,
and Babinski’s signs may be also seen.7,9 The age of onset is
usually in the third or fourth decade, and neuropatholog-
ically, the degeneration of multiple systems is observed.10
Only two families have been genetically conﬁrmed as
having SCA4: one is the original SCA4 family that is of
Scandinavian origin but resides in the United States,7
and the other is a German family.9 Discovery of the muta-
tions is needed to settle the question as to whether SCA4
and SCA31 are allelic diseases.11
We previously reported that a single-nucleotide change
(16C > T) in the PLEKHG4 (puratrophin-1) gene
(MIM *609526) is tightly associatedwith SCA31.6 However,
two patients who did not have this change were subse-
quently found,12,13 indicating that the 16C > T change
in PLEKHG4 is a marker in a strong linkage disequilibrium
with SCA31 but is not the cause of this disease. Conducting
ﬁne SNP typing allowed the SCA31 critical region to be
tracked to a 900 kb ‘‘founder’’ chromosome lying between
rs11640843 (SNP0413) and 16C > T in PLEKHG4.6
Whereas all SCA31 patients shared a single haplotype for
this critical region, none of the controls (800 Japanese
and 60 white American control chromosomes) had it,
indicating that SCA31 is caused by a single founder
mutation.13 Previous attempts to ﬁnd this mutation by
PCR-based sequencing in all annotated coding exons and
expressed sequence tags (ESTs) failed. The strong founder
effect in SCA31 made a mutation search complicated
because segregating genetic changes are not always causa-The Americantive. Therefore, we needed to identify all the genetic
changes and then investigate which one was the causative
mutation.
In this study, we carried out a comprehensive mutation
search, including Southern blot analysis to detect any chro-
mosomal rearrangements and BAC- and fosmid-based
complete genome sequencing to identify all the genomic
changes in the 900 kb critical region. Here we show that
SCA31 is associated with an inserted sequence that consists
of complexpenta-nucleotide repeats containing (TGGAA)n.
Material and Methods
Human Samples
Study Subjects
We collected blood samples after obtaining informed consent
from all involved SCA31 families, a small nuclear family of Amer-
ican SCA4 kindred7, and controls. The study conformed to the
tenets of the Declaration of Helsinki, and the ethics were approved
by the institutional review board of Tokyo Medical and Dental
University, Tokyo, Japan.
Genomic DNA was extracted on the basis of a standard
protocol.6 The SCA31 subjects studied were 160 affected individ-
uals from 98 SCA31 families, consisting of the previously
described 125 affected individuals from 64 families13, an indi-
vidual from the ‘‘U09’’ family without the 16C > T PLEKHG4
change13, and 34 newly recruited individuals from 33 families.
Normal controls consisted of 400 Japanese and 30 white American
individuals, in whom no personal or family histories of ataxia or
any inherited disorders had been documented. Five individuals
from the original SCA4 kindred (kindred 18757), including three
with typical SCA4 symptoms and SCA4 disease-haplotypes, were
also studied. In addition, the previously described 21 individuals13
who had a similar clinical phenotype but did not carry the SCA31
founder haplotype were also included as disease controls for muta-
tion analysis.
Among the SCA31 individuals, one homozygous patient in
family P214 who harbored two identical SCA31 haplotypes
between D16S3094 and D16S3095, covering the SCA31 critical
interval, was chosen for a complete BAC- and fosmid-based
genomic sequencing of the SCA31 critical region. The same homo-
zygous patient, a heterozygous SCA31 patient in family P145,
and a normal control (control 1) were chosen for investigation
by Southern blotting, quantitative genomic PCR, and array-based
comparative genomic hybridization (aCGH) analyses. Mutation
candidates found through these analyses were then screened in
the remaining SCA31 and control individuals.
The penta-nucleotide repeat insertion (see Results) was tested
either by Southern blotting, PCR, or both in all SCA31 individuals,
ﬁve individuals from an SCA4 family, and all controls (430 normal
controls and 21 disease controls). Thirty-nine SCA31 heterozygous
patients, from whom we could obtain detailed clinical informa-
tion and ages of onset, were analyzed for the correlation between
insert length and age of onset. One affected SCA4 individual
and ten disease controls were screened for mutations in the
critical genes, BEAN (brain expressed, associated with Nedd4)
(MIM *612051) and TK2 (thymidine kinase 2) (MIM *188250),
and in EST FLJ27243 (see Results) by PCR and direct sequencing.
Brain Tissue Samples
Frozen brain tissues of the cerebellar cortex were used for gene
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analyses, and ﬂuorescence in situ hybridization [FISH]). In addi-
tion to the cerebellar cortex, the cerebral white matter (frontal
lobe), the frontal cortex, hippocampus, thalamus, and the
midbrain from a control individual were studied for RT-PCR anal-
ysis. Both control and SCA31 brains were obtained during an
autopsy performed under their families’ written consent and
approved by each institutional ethics committee. These brains
were immediately frozen and stored at –80C until use. Four
control frozen brains were studied: two were from patients with
sporadic amyotrophic lateral sclerosis (ages at death: 70 and 78
years), one was from a patient with SCA3/MJD (age at death: 65
years), and one was from a patient who had autosomal-dominant
progressive external ophthalmoplegia (adPEO) (MIM #157640)
and a heterozygous missense mutation in the nuclear-encoded
DNA polymerase-g gene (age at death: 72 years). Neuropatholog-
ical examinations of these patients did not show obvious neuronal
losses in the cerebella. For SCA31, two patients were studied (ages
at death: 74 and 78 years).
Mutation screening
Southern Blotting
We screened for genomic rearrangement by performing Southern
blot analysis and using cosmid clones for probe synthesis. The
method has been previously described.6,15 In brief, we generated
cosmid clones, tandemly covering the SCA31 critical region, by
subcloning from the BAC contig constructed on the basis of
a control human genome.16 Probes radiolabeled with 32P were
then generated from each cosmid clone. Genomic DNA extracted
from lymphoblastoid cell lines of three individuals (one control
individual, an SCA31 homozygote, and a heterozygote) was di-
gested with a restriction enzyme and subjected to Southern blot
analysis. The analysis was undertaken with ﬁve different restric-
tion enzymes (BamHI, EcoRI, EcoRV, HindIII and XbaI). When
needed to conﬁrm results, another ﬁve SCA31 subjects and ten
normal controls were similarly investigated.
Altered restriction enzyme fragment patterns were observed
with the cosmid probe detecting the genomic region between
65,083,571 and 65,124,051 on NCBI Build 36.3. We conﬁrmed
the results by employing PCR products as a probe that had
been obtained by ampliﬁcation of a 3009 bp segment (from
65,079,127–65,082,135) within this genomic region and radiola-
beled with 32P. This PCR reaction was carried out with primers
Ins-long3.0k-F (50-GCTTCTCTGCTTCTGTCATCAGCTCAC-30) and
Ins-long3.0k-R (50-ATCTTTCCACACTACCATCCCATCCAG-30); con-
trol genomic DNAwas used as a template.
Sequencing of the 900 kb SCA31 Critical Region
This was performed by a modiﬁed version of the methods used in
Chromosome 21 genome sequencing.17,18
Construction of a BAC Library of the Genomic DNA from the Lym-
phoblastoid Cell Line Derived from a Homozygous SCA31 Patient.
The lymphoblastoid cells derived from the homozygous SCA31
patient14 were embedded in agarose gel plugs, and high-molec-
ular-weight genomic DNA was extracted. The DNA was partially
digested with HindIII, and fragments from 100–150 kb were
selected by pulse ﬁeld gel electrophoresis (PFGE). The collected
DNA fragments were ligated with pBAC-lac18 and subsequently
used for transformation of DH10B cells by electroporation.
Transformed E. coli were spread on lysogeny broth (LB) plates
with 12.5 3 103 g/liter of chloramphenicol, X-gal (5-bromo-4-
chloro-3-indolyl-b-D-galactopyranoside), and IPTG (isopropyl
b-D-1-thiogalactopyranoside). Positive colonies were selected by546 The American Journal of Human Genetics 85, 544–557, Novemcolor, picked up, and separately stored in LB liquid medium with
7.5% (v/v) glycerol and 12.5 3 103 g/liter chloramphenicol (LB-
glycerol-Cm) prepared in 384-well plates. A total of approximately
115,000 clones were obtained. In order to evaluate the quality of
the BAC library, we randomly selected 200 clones, isolated their
BAC DNA by the alkaline-SDS (sodium dodecyl sulfate) method,
and digested it with NotI. Their insert sizes were measured by
PFGE. Approximately 90% of BAC clones had DNA inserts of
80–140 kb in length, and themean size was approximately 110 kb.
Construction of a Fosmid Library of the Genomic DNA of the Same
Homozygous Patient. Genomic DNA extracted from the lympho-
blastoid cell line from the same homozygous patient14 was
sheared, and fragments ranging in length from 35–50 kb were
collected. The DNA fragments were cloned into pCC1FOS vector
(Epicenter) with the CopyControl Fosmid Library Production Kit
(Epicenter) according to the manufacturer’s instructions. Approx-
imately 250,000 clones were collected in LB-glycerol-Cm pools,
each of which contained 2,000–10,000 clones. Examination of
96 randomly selected clones conﬁrmed that each clone harbored
a DNA insertion of approximately 35–45 kb.
Identiﬁcation of BAC and Fosmid Clones Covering the SCA31 Crit-
ical Region. We spotted approximately 115,000 BAC clones in a
grid pattern on GeneScreen Plus membranes (PerkinElmer) with
a 4 3 4 double offset pattern by using a BioGrid robot (BioRo-
botics) to make high-density replica (HDR) ﬁlters. We created
probes by amplifying the genomic DNA of the same patient by
PCR to detect every 50 kb segment in the critical region. After
labeling the probes with 32P, we hybridized the HDR ﬁlters with
them. Fifty-two BAC clones were identiﬁed as positive clones.
The insert ends of these 52 BAC clones were sequenced, and 48
clones were mapped to the 900 kb critical region, whereas the
remaining fell into different chromosomal regions.
We constructed a fosmid library to clone the genomic region
(approximately 42.3 kb in length) that was missed in the BAC
library. Four sites in the region were chosen as PCR targets, and
primers that would allow their speciﬁc ampliﬁcation were used.
By serial PCR, the pools identiﬁed as harboring the desired clones
were divided into smaller pools, and subsequently three fosmid
clones covering the 42.3 kb region were isolated.
Complete Sequencing of the BAC and Fosmid Clones Covering the
900 kb Critical Region. Twelve BAC and three fosmid clones formed
a contig that covered the entire 900 kb critical region and thus
were rendered for sequencing (Table 1). The complete base
sequences of all but one BAC clone (Ca0215J24) and one fosmid
clone (CaFos003) were determined by shotgun sequencing as
previously described.17 In brief, every BAC and fosmid clone was
sheared into short fragments of approximately 4 kb, treated with
shrimp alkaline phosphatase, and then subcloned into pCR-blunt
II vector (Invitrogen). The plasmid was used for transforming
DH10B by electroporation. Seven hundred and sixty-eight sub-
clones from each BAC clone and 384 subclones from each fosmid
clone were picked up. Each was inoculated into 160 ml of LB with
glycerol and kanamycin, grown overnight, and then rendered
for rolling-circle ampliﬁcation (RCA) with the Templiphi DNA
Ampliﬁcation Kit (GE Healthcare Bioscience). Ampliﬁed subclone
plasmids were sequenced withM13 primers and the BigDye Termi-
nator v3.1 Cycle Sequencing Kit (Applied Biosystems) in ABI
PRISM 3730 and 3100 (Applied Biosystems). The raw sequence
data were analyzed and assembled with phred, phrap, and consed.
The remaining two clones, Ca0215J24 and CaFos003, were
sequenced so that the gaps between Ca0217F15 and Ca0262A14
and between CaFos001 and CaFos002, respectively, could be ﬁlled.ber 13, 2009
Finally, the obtained nucleotide sequence information in the
SCA31 critical interval of the homozygous patient was compared
with a public database (NCBI, build 36.3). For each discordant
nucleotide sequence, 20 pilot control individuals were examined
so that it could be determined whether such discordance was
simply due to polymorphism. If the discordance was not proven
to be polymorphism, a larger number of controls (n ¼ 430) and
SCA31 patients were analyzed. With this approach, nucleotide
sequences that segregate with SCA31 in the entire 900 kb critical
region were searched.
Quantitative Genomic PCR and aCGH
Quantitative genomic PCR was performed with TaqMan probes
(Applied Biosystems) designed to measure two exons of each
gene within the SCA31 critical region as previously described.19
Gene dosage was also analyzed by custom-designed, high-deﬁni-
tion array-based comparative genomic hybridization (aCGH)
microarrays (Agilent Technologies). Oligonucleotide probes were
designed by two of us (Y.T. and S.T.) according to the published
method.20,21 A 1.88 Mb genomic region between D16S3031 and
D16S3107 (NCBI, build 36.3), completely covering the 900 kb
SCA31 critical region, was included in the microarray, and probes
were designed with an average interval of 100 bp. Genomic DNA
samples of three individuals (one homozygous patient,14 one
heterozygous patient, and one control subject) were tested and
compared with each other.
Characterizing the Penta-Nucleotide Repeat Insertion
Analysis of the Penta-Nucleotide Repeat Length by PCR
and Agarose-Gel Electrophoresis
The genomic DNA of the patients was ampliﬁed by PCR with
primers 1.5k-ins-F (50- ACTCCAACTGGGATGCAGTTTCTCAAT-30)
and 1.5k-ins-R (50- TGGAGGAAGGAAATCAGGTCCCTAAAG-30).
Table 1. Genomic Regions Cloned by 12 BACs and Three Fosmids
that Were Rendered for Sequencing
BAC or Fosmid Clone
Cloned region on NCBI Build 36.3
from to
Ca0109N14 64,935,119 65,053,675
Ca0159N04 65,052,547 65,166,347
Ca0041G15 65,163,955 65,252,631
Ca0080M24 65,215,426 65,328,653
Ca0303C23 65,265,426 65,358,989
CaFos001 65,345,373 65,382,103
CaFos003 65,369,225 65,410,300
CaFos002 65,385,244 65,430,086
Ca0151F23 65,401,149 65,500,053
Ca0312C05 65,485,609 65,608,342
Ca0238A16 65,530,876 65,635,257
Ca0217F15 65,634,014 65,724,706
Ca0215J24 65,692,848 65,788,160
Ca0262A14 65,726,364 65,829,738
Ca0154D03 65,815,462 65,917,148
Together, the 12 BACs and three fosmids formed a contig covering the entire
900 kb critical region.The AmericanEach PCR reaction was performed in a ﬁnal volume of 10 ml, con-
taining 0.25 mM of each primer, 400 mM (each) of dNTP, 1.5 mM
of MgCl2, 0.25 U of LA Taq HS polymerase (Takara Bio), and 50–
100 ng of genomic DNA. Thermal cycles were as follows: initial
denaturing at 95C for 5 min followed by 30 cycles of denaturing
at 95C for 20 s and annealing and extension at 68C for 8 min.
Five microliters (5 ml) of each PCR product was digested with
HaeIII and then run through an 0.8% agarose gel at 30 V (V) for
15 hr with 1 kb DNA Ladder (Takara Bio).Whenmultiplemembers
were collected, differences in the length of insertionwere analyzed
in the same gel.
The lengths (L ¼ length) of HaeIII-digested PCR products (L/kb)
were calculated as below. The electrophoretic migration distance
(d; in millimeters) of each sample was measured and then intro-
duced into the formula: d ¼ alnL þ b, in which ‘‘a’’ and ‘‘b’’ were
determined by the standard line obtained from the data of the
size markers. As the HaeIII-digested PCR product has 193-bp
sequences ﬂanking the SCA31 penta-nucleotide repeat insertion,
the length of the insertion was calculated as L – 0.19/kb. The corre-
lation between the length of the repeat insertion and the age of
onset was analyzed via calculation of Pearson’s product-moment
correlation coefﬁcient (r).
Sequencing of the Penta-Nucleotide Repeat in SCA31 Patients
and Two Controls
PCR products including the penta-nucleotide repeat were ob-
tained as described in the previous section. We ﬁrst analyzed the
repeat sequences in ﬁve SCA31 patients by direct sequencing
of the gel-extracted, puriﬁed PCR product with primers 010-1F
(50-CATAGTGGCACATGCATGTAGTC-30) and 10R (50-CCCAGGC
TGGAGTGCAGTGAC-30) to see the conﬁgurations of the insertion
sequences. Using the same method, we investigated nucleotide
sequences at the insertion site in ﬁve normal controls so that we
could see the (TAAAA)n repeat numbers (see Results). Because we
found two exceptional controls (controls 1 and 2) harboring
smaller insertions, we also sequenced these insertions by the
same method.
Because the simple repeat sequences in the insertion extended
too long to be read through, shotgun sequencing was also per-
formed in the homozygous patient and on the allele with an inser-
tion from control 1. For this shotgun sequencing, puriﬁed PCR
products were directly sheared by HydroShear (Genomic Solu-
tions). Ninty-six colonies were picked up for each PCR product
and sequenced as done in BAC and fosmid shotgun sequencing.
The obtained sequence data were assembled and analyzed with
phred, phrap, and consed.
Analysis of Gene Expression
Poly-Aþ RNA obtained from frozen human cerebellar tissues was
reverse-transcribed with SuperScript III (Invitrogen). Because the
insertion site was not annotated in the public database as being
associated with any genes, we independently examined whether
the repeat insertion could be transcribed. We designed primers
around the repeat insertion site with 300–1000 bp intervals and
attempted to amplify the site by PCR with various pairings of
primers. If ampliﬁcation was successful, we cloned the PCR prod-
ucts into pCR2.1-TOPO (Invitrogen) and cycle-sequenced them to
ﬁnd previously unidentiﬁed transcripts.
Gene expression in various human tissues was examined by PCR
with the primers listed in Table S1. HumanMultiple Tissue Panels I
and II (Clontech, BD Bioscience) as well as various brain regions
obtained from control brains at autopsy were used. For the identi-
ﬁcation of full-length transcripts, 50- and 30-rapid cloning of theJournal of Human Genetics 85, 544–557, November 13, 2009 547
cDNA ends (RACE) and RT-PCR analysis of control human cere-
bellar cDNA were performed. Expressions of newly identiﬁed
transcripts were also conﬁrmed by PCR screening of a human
cerebellar cDNA library (Takara Bio, Inc.). When necessary,
strand-speciﬁc RT-PCR was performed according to the method
previously described.22
Quantitative RT-PCR
Quantitative PCR of cDNA was carried out by the TaqMan expres-
sion chemistry protocol with an ABI Prism 7700 Sequence Detec-
tion System (Applied Biosystems). Primers and probes used in this
study were designed by the manufacturer (Table S2). Quantities
measured by analysis were adjusted for glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) with TaqMan GAPDH Control
Reagents (Applied Biosystems). Analyses were repeated three
times for each sample, and results were compared between the
patient (n ¼ 2) and control (n ¼ 4) groups.
Fluorescence In Situ Hybridization for Detecting
RNA Foci
The detection of the repeat transcripts in Purkinje cells by FISHwas
carried out as previously described23 with digoxigenin (DIG)-
labeled, locked nucleic acid (LNA) probes (Exiqon) (Table S3). The
brain samples of the two SCA31 patients and four control subjects
were analyzed in this part of the study. Frozen cerebellar cortex
samples obtained at autopsy were stored at 80C and sectioned
at 10 mm thickness in a cryostat. Sections were ﬁxed for 30 min at
room temperature in 4% paraformaldehyde in PBS. After ﬁxation,
sections were washed and treated with 50% formamide, 23 SSC
(300 mM NaCl and 30 mM sodium citrate [pH 7.0]) for 10 min at
room temperature. Sections were then hybridized overnight at
37C with a solution containing probe (1 ng/ml), 40% formamide,
23 SSC, 0.2% bovine serum albumin (BSA), 10% dextran sulfate,
2 mM vanadyl adenosine complex, and 1 mg/ml each of yeast
transfer RNA and salmon sperm DNA. After being washed three
times for 30 min at 45C with 50% formamide and 23 SSC, the
probe was detected with anti-DIG antibody Fab conjugated with
alkaline phosphatase (Roche) and visualized with HNPP/FastRed
(Roche) according to the manufacture’s protocol. After nuclei
were stained with 40, 6-diamidino-2-phenylindole (DAPI), sections
weremountedwith an aqueousmounting kit. The speciﬁcity of the
RNA foci was conﬁrmed both by detection of foci with different
stringencies in experiments and by veriﬁcation that they disap-
peared with RNase A treatment, but not with DNase. At least ten
Purkinje cells were observed in each section.
Recombinant Glutathione-S-Transferase-Fused
Splicing Factor Protein Synthesis and the
Electrophoretic Mobility-Shift Assay
To further clarify the pathogenic implication of transcribed repeat
insertion, we looked for proteins that could potentially bind to the
transcribed repeats. Based on the fact that the SCA31 repeat
sequence was related to satellite sequence in heterochromatin
(see Results), and also based on consultation with ESEﬁnder 3.0,
we found two serine/arginine-rich splicing factor proteins (SR
proteins), SFRS1 and SFRS9, that were good candidates for binding
to transcribed SCA31 insertions.
Recombinant GST-fused SR proteins were synthesized as
follows. The cDNA of the full-length coding regions of SR proteins
(SFRS1-1: NM_006924.4; SFRS1-2: NM_001078166.1; and SFRS9:
NM_003769.2; all in NCBI) were ampliﬁed by PCR from a cDNA548 The American Journal of Human Genetics 85, 544–557, Novemlibrary of human cerebellum (Takara Bio) with custom primers
(Table S4). SFRS1-1-R corresponds to SFRS1 isoform 1 (SFRS1-1)
and SFRS1-2-R to SFRS isoform 2 (SFRS1-2). The PCR products
were double digested with EcoRI and SalI and cloned in frame
into the EcoRI-SalI site of the pGEX-6P1 vector (GE Healthcare
Bioscience). The SR-protein constructs were ﬁrst introduced into
JM109, ampliﬁed, and then used for transforming the BL21 strain
of E. coli.
The GST-fused SR proteins were harvested by a modiﬁed version
of the previously described method.24 In brief, 500 ml of trans-
formed BL21 cell cultures was induced with 0.5–1.0 mM of IPTG
for 3 hr, and the collected cells were suspended in 50 mM Tris-
HCl (pH 8.0) and 150 mM NaCl. The E. coli were sonicated and
treated with 0.02% DNase, 1 mg/ml lysozyme, and 1 mM PMSF.
GST-fused proteins were puriﬁed from the soluble fraction with
Glutathione Sepharose 4 Fast Flow (GE Healthcare Bioscience)
and eluted with 50 mM Tris-HCl (pH 8.0) and 20 mM glutathione.
After dialysis, the concentrations of the proteins were measured
by BCA assay. GST-SFRS1-1 and GST-SFRS9 were successfully
synthesized, whereas GST-SFRS1-2 was poorly collected in the
soluble fraction. GST-SFRS1-1 was used as the representative of
GST-SFRS1 in the subsequent study.
For electrophoretic mobility-shift assays (EMSAs), the synthetic
RNA oligonucleotides, (UGGAA)8, (UAGAA)8, and (UAGAAUA
AAA)4, were labeled with digoxigenin (DIG). The RNA probes and
the speciﬁc competitors, unlabeled (UGGAA)8, (UAGAA)8, and
(UAGAAUAAAA)4, were denatured at 94
C and immediately used
for the following procedures. RNA probes (1.5 pmoles) were mixed
with 2.4 3 107 g of either synthetic GST-fused protein or GST
alone, different concentrations (0- to 100-fold the concentration
of the probe) of one of the speciﬁc competitors, and 4 nM of poly
[d(A-T)] in a 20 ml solution of 20 mM HEPES (pH 7.6), 1 mM
EDTA, 10 mM (NH4)2SO4, 1 mM DTT, 0.2% (w/v) Tween 20, and
30 mM KCl. The mixtures were incubated for 25 min at room
temperature and then placed on ice. After dilution of the mixtures
with 0.53 TBE buffer to give one-ﬁfth of the original concentra-
tions, the protein-boundprobeswere separated from the free forms
bybeing run through6%nativepolyacrylamidegels at 30V in0.53
TBEbuffer. The separatedRNAprobeswere transferred to positively
charged nylon membranes by a semi-dry method and then de-
tected with the DIG Luminescent Detection Kit (Roche) according
to the manufacturer’s instructions.
In Silico Location Search of Penta-Nucleotide Repeats
To reveal the origin of complex penta-nucleotide insertion, we
searched locations in the human genome where repeat sequences
(TGGAA)n, (TAGAA)n, and (TAAAATAGAA)n were abundantly
present. For this purpose, repeat sequences were set unmasked,
and then locations of (TGGAA)40, (TAGAA)40, and (TAAAATA
GAA)3 were searched for in the ‘‘reference only’’ human genome
by BLAST. The best-matched 500 locations with E value <
0.0001 were selected and were shown in ‘‘genome view’’ according
to the degree to which they matched. We then checked the
matched sequences manually to conﬁrm that pure stretches had
been correctly selected. The resultant locations were shown in
chromosome ﬁgures.
Mutation Screening in the SCA4 Family
and 21 Disease Controls
To investigate the genetic relationship between SCA31 and SCA4,
we screened ﬁve DNA samples from the American SCA4 family7 byber 13, 2009
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Figure 1. A Comprehensive Physical Map of the 900 kb SCA31 Critical Interval between rs11640843 and 16C > T in the PLEKHG4
Gene
This region was entirely covered without gaps by 12 BAC and three fosmid clones derived from a SCA31 homozygous patient.
These clones were sequenced. An insertion ranging in length from 2.5–3.8 kb was found at nucleotide number 65,081,803 on human
chromosome 16 on NCBI build 36.3 between BEAN and TK2.performing PCR-based direct sequencing of all coding exons and
exon-intron boundaries of BEAN, TK2, and FLJ27243 by using
40 primer pairs (shown upon request). Southern blot analysis in
the genomic region encompassing BEAN and TK2 (positions
from 65,160,201–65,932,756 on chromosome 16, NCBI build
36.3) was also performed similarly to the SCA31 mutation search.
The 21 disease controls13 who did not have the SCA31 founder
haplotypes were also tested for the insertion. Ten out of these
21 individuals were additionally screened for any mutations in
BEAN, TK2, or in FLJ27243 with the same 40 primer pairs as those
used for SCA4.
Results
Southern Blot Analysis Revealed a 2.5–3.8 Insertion
Consisting of Complex Pentanucleotide Repeats
Containing (TGGAA)n in SCA31 Patients
Figure 1 shows a comprehensive physical map of the
SCA31 critical region. Screening of this 900 kb critical
region by Southern blotting allowed us to identify an inser-
tion at nucleotide number 65,081,803 on human chromo-
some 16 on NCBI build 36.3 (Figures 2A and 2B). There
were no other gene rearrangements in the entire critical
region. The insertion was found in all 160 affected individ-
uals from 98 SCA31 families, including the individual in
the U9 family previously described,13 and ranged in length
from 2.5–3.8 kb. PCR ampliﬁcation followed by direct
sequencing or shotgun sequencing of the insert disclosed
that the insertion consisted of a preceding four nucleo-The Americantides, ‘‘TCAC,’’ and the three penta-nucleotide repeat
components (TGGAA)n, (TAGAA)n, and (TAAAA)n in all
SCA31 patients tested (Figure 2C). In the homozygous
patient’s repeat, which was sequenced by the shotgun
method, a pure (TGGAA)n stretch extended for at least
110 repeats, presumably for more than 1 kb in light of
the size of the sheared DNA fragment. Pure (TAAAATA
GAA)n also stretched for more than 112 repeats. These
pure repeat sequences were separated by a bridging
sequence and (TAGAA)46.
In contrast to SCA31 chromosomes, the vast majority of
controls (99.77% among 800 Japanese and 60 white Amer-
ican chromosomes) did not have any insertions. The 21
disease controls and SCA4 subjects also did not have this
insertion. Very rarely, however, insertions were observed
in two individuals (2/860 chromosomes: 0.23%) (controls
1 and 2) (Figure 2A, left-hand panel). PCR ampliﬁcation
and sequencing showed that the inserts were in the same
position as in the SCA31 patients, and their lengths were
1.5 kb in control 1 and 2.0 kb in control 2. Sequencing
analysis of controls 1 and 2 disclosed that they both had
inserts with a preceding 4 base ‘‘TCAC,’’ (TAAAA)n, (TA-
GAA)n, and (TAAAATAGAA)n stretch (Figure 2D). However,
no (TGGAA) sequences were observed. Because these indi-
viduals did not manifest any cerebellar signs or have any
documented histories of inherited diseases in their fami-
lies, we considered that these inserts with complex
penta-nucleotide repeats were not pathogenic, or at least
did not have enough toxicity to develop a disease duringJournal of Human Genetics 85, 544–557, November 13, 2009 549
AB
ACTCCAACTGGGATGCAGTTTCTCAATCAAAGGGATATGAACTGCCCTGGCCACTGAATTCAGAGAACATTGTAGGGGGCAGGGGAGTTGGGAGCAGG
GAGCAGAGATCCCAGCTGTGACGAGCCCAGGTCTGAGGCAGCTCCAAGACCAAGCACCCAGGTGGCTGTCCTTCCTGGCGACTGGAGAGGCAGGAGC
CCAGCAGAGTCTCATAGAAAGCAAATGACAATCAAGACCCAGGTCCTCAGCCAGATGCGGTGGCTCATGCCTGTAATCTCAGCACTTTGGGAGGCCAAA
GTGGGCAGATCACCTCAGGTCAGGAGTTTGAGATCAGCCTGGCCAACATGGTGAAATCCCATCTCTACTAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTA
GCCAGGCATAGTGGCACATGCATGTAGTCCCAACTACTTGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGAAGGTGGAAATTGCAGTGGGCCAAG
ATCACGTCACTGCACTCCAGCCTGGGCAACAAAACAAGACTCTGTTTCAA-(insertion)-TAAAATAAAATAAAATAAAATAAAATAAAATAAAATAAAATAAA
ATAAAATAAAATAATAAAATAAAAAGAAACCTCTAAATTGATTGAGATCTGCCTCCGACACTTTTCAATTTACAAAAACATACCTAAGAATTGGCCACCCAG
GGGCAGGAAGCTGGGGTTTCTATCCAGTAACTCTCACCCCGCTGGCCCTTGGTTGGTTGAGGGTCGCCACCTTCCTGGCGCTTCCAGCCTGTCCCGCA
CACTAGCAGAGTATGCCTCTGCAGCCAGCAGCACTCAAGGCATGAGGCATTACTGGGGATATCTGGATGGGATGGTAGTGTGGAAAGATGCAGATGCT
GATGTGCCTGGTCTTCATTTTTTGTGGGGCAGGGGGACAAAGAAAGGACAAATCCTGACCTAGGCCCTGCTCCACTGGGAGGGGCCCGGTCACCCTCC
AATCTCAGCTTTTCAGAGTGACAAGCAGTGGCAGGGCCTGGCTGCACATAGCTTTATCTCTTGCTAGCACAACTTCCTCCTTTGCTTCCAGATTGGGCTT
TGGAGCAGGAGAGGCAGGACCCATCCATTCCTCCAAGTGCCCAGCCTGAGCCTGGCCTGGGACAGGACTCTATCCTCCATATCCAGCCCCCCCGAAGC
CACCATGAGCAGGTCCCAATCCCCAGGCCCAGGCGAAGCTGCTCTGGGTGAGACCCTCCTGGGCAACATCATCAGCTACTACCAGGAGAGAGCAGGG
GAGGGCCGGCTCGATGTCTGCAGGCAAGCAGCCCTCACCCACAGGGCCAGGTGGCTCCTGGGCAGGAGGGCCCCTCCATGGCTCTGTCTGCCAGAG
GAAGTGGCCCTTGCTCTGGGTGGCTGCTGTTGTGGGGATCCCAGCCCTGTCCCAAAAGTCAGCCCTGAGCTGGTGCATGCACTAGAGTTCCTGGAGCT
GATCTCTGTCAACCTGCTTCTGTTTCCCTGGAGGAAGGAAATCAGGTCCCTAAAG
C
D   [ TCAC (TAAAA)2 AAA (TAAAA)3-5 AA (TAAAA)2 TA TAAAA TAGAA TAAAA (TAGAA)n(TAAAATAGAA)n ]
(allele frequency: 0.23% in control)
(TAGAA)46(TGGAA)n
SCA31 insertion sequence:
[ TCAC TAAAA (TAGAA)2 (TGGAA)n TGGGAA TGGAA TGGGAA (TAGAA)2 (TGGAA)2 (TAGAA)2 TGGAA (TAGAA)46 (TAAAA TAGAA)n ]
1) Pure (TGGAA)n stretch
2) Complex (TGGGAA), (TGGAA) and (TAGAA) sequence (shown with red double line)
3) (TAAAA TAGAA)n stretch
Figure 2. Identification of Complex Pentanucleotide Repeat Insertions in SCA31 Patients
(A) Southern blot analysis showing the SCA31 insertion. The left-handpanel shows EcoRI-digested genomic fragments detectedwith a cos-
midprobe for the regionbetweennucleotides65,083,571and65,124,051.A rare1.5kb insertionandanunusual 0.7kbexpanded (TAAAA)n
(both shownwith solid black arrows)wereobserved inone control (control 1). SCA31 insertions in twopatients are shownwith a red arrow.
‘‘Hom.’’ and ‘‘Het.’’ designate the homozygous patient andheterozygous patient, respectively. The dotted arrow indicates normal chromo-
somes without insertions. The thick 5.8 kb bands common in the three subjects show fragments outside the insertion site. The right-hand
panel shows aberrant EcoRI-digested 9–10 kb genomic fragments (a red arrow) that completely segregated with SCA31 patients (P). All
heterozygous patients (P) and controls (C) have ‘‘normal’’ 6 kb fragments (dotted arrows). Radiolabeled PCR products obtained by ampli-
fying the 3009 bp genomic segment between nucleotides 65,079,127 and 65,082,135 on NCBI build 36.3 were used as probes.
(B) Sequences around the SCA31 insertion (chromosome16: nucleotides 65,081,260–65,082,786 on NCBI build 36.3). Flanking primers
for PCR ampliﬁcation (underlined in red) of insertion and ﬂanking HaeIII recognition sites (in shaded boxes) are shown. The AluSx
sequence30 is shown with a green underline. Without an insertion, PCR ampliﬁcation with ﬂanking primers and a subsequent HaeIII
digestion will produce a DNA fragment 193 bp in length.550 The American Journal of Human Genetics 85, 544–557, November 13, 2009
the human lifespan. Therefore, we concluded that the
insertions in SCA31 patients exerted their toxicity either
because of their lengths (> ¼ 2.5-kb) or because of their
(TGGAA)n component, which made a clear distinction
between SCA31 and the rare control insertions.
The insertion site was identical for all insertions, and the
junction point of the insertion was located at the 30-tail of
an AluSx25 (Figure 2B). Alu variants have previously been
linked to certain disease loci, such as DM1, HD, Friedreich
ataxia (FRDA) (MIM #229300), and fragile X syndrome
(FRAXA) (MIM #300624).26 There is a related short
penta-nucleotide repeat of (TAAAA)n immediately down-
stream of the insertion site (Figure 2B). This (TAAAA)n
was polymorphic (‘‘n’’ usually ranged from 8–21), and a
very rare expansion up to approximately 140 repeats was
observed in one out of 860 control chromosomes
(frequency: 0.12%) (control 1, shorter allele; see Figure 2A,
left-hand panel). Both (TAAAA)n and the SCA31 founder
insertion are polypurine tracts interrupted with thymi-
dines. SCA31 is similar to Friedreich’s ataxia (FRDA) in
that they both contain ‘‘GAA.’’
The Length of the SCA31 Insertion Is Inversely
Correlated with the Age of Onset
The SCA31 penta-nucleotide repeat insertion ranged from
2.5–3.8 kb in length (Figure 3A). Although SCA31 is a
disease with a strong founder effect, the fact that the
length of the insertion varied by ~1.3 kb among families
(C) The components of the SCA31 insertion in the homozygous patient. The SCA31 insertion consists of a preceding 4 bp TCAC and
three different penta-nucleotides, (TGGAA)n, (TAGAA)n, and (TAAAA)n. (TGGAA)n is the patient-speciﬁc repeat (shown in red), and
both (TGGAA)n and (TAAAATAGAA)n are pure stretches too long to be read through. The bridging sequence between (TGGAA)n
and (TAGAA)46 is underlined in red.
(D) The sequence of the insertion in control 1. Rare insertions were observed in controls at the same position as the SCA31 insertion, but
with shorter length and different components. The insertion in control 1 consisted of a preceding 4 bp TCAC and two pentanucleotide
components, (TAGAA)n and (TAAAA)n. The (TGGAA)n was not detected.
Figure 3. The Length of Insertion Inversely
Correlates with Age of Onset in SCA31
(A) PCR ampliﬁcation and agarose gel electro-
phoresis showing that the length of the inser-
tion differs among SCA31 families.
(B) A scatter plot showing an inverse correla-
tion between the length of the SCA31 inser-
tion and the age of onset. The length of the
repeat insertion was inversely correlated
with age of onset (Pearson’s product-moment
correlation coefﬁcient r ¼ –0.41, p ¼ 0.010,
n ¼ 39.).
(C) A slight expansion of the SCA31 insertion
observed in one SCA31 family. Individual #4
has a slightly longer insertion than the others
(#1–#3) in the same SCA31 family. This indi-
vidual #4 is in the youngest generation
among them.
suggests that the insertion was not
completely stable during multiple trans-
missions from one or a few principal
ancestors. Importantly, a signiﬁcant
correlation was observed in that patients
with longer repeats show earlier disease onset (r ¼ –0.41,
p ¼ 0.010, n ¼ 39) (Figure 3B). Very mild anticipation
(younger age of onset in future generations) is sometimes
observed in SCA318, which suggests that the insertion
might have a propensity for expansion. Indeed, we de-
tected a subtle expansion of the inserted repeat within
one SCA31 family (Figure 3C).
Complete Genomic Sequencing of the 900 kb Critical
Region Unveiled Only Two Mutation Candidates
Because of the strong founder effect in SCA31, we needed
to detect all genetic changes in the critical region. For this
reason, we also performed BAC- and fosmid-based shotgun
sequencing over the entire 900 kb SCA31 critical region.
Upon completing entire sequencing in the homozygous
patient, we initially found 336 sites annotated differently
from the reference sequence (NCBI build 36.3). However,
most of these 336 changes were also found in the controls,
allowing us to exclude them asmutation candidates. In the
course of this effort, we also investigated 34 new SCA31
patients and found that two independent SCA31 patients
shared the disease-speciﬁc haplotype only between
AB473214 and AB473219 (Table 2). As a result, we ﬁnally
found that the penta-nucleotide repeat insertion and a
single-nucleotide change (AB473217) at 65,114,245 are
the only genetic changes segregating with the disease.
This single-nucleotide change (AB473217) is in an intron
of the TK2 (thymidine kinase 2) gene, 4,964 nucleotidesThe American Journal of Human Genetics 85, 544–557, November 13, 2009 551
Table 2. The Haplotypes of Representative SCA31 Patients and Control Subjectsdistant from the nearest splice junction. RT-PCR analysis
did not indicate the presence of aberrant transcripts in
SCA31 patients (data shown upon request). Quantitative
genomic PCR and aCGH did not show copy-number vari-
ations in the SCA31 critical region (data shown upon
request). Taking all these data together, we considered
that the complex penta-nucleotide repeat insertion con-
taining (TGGAA)n was the only mutation that could plau-
sibly cause SCA31. Further efforts were focused on this
repeat insertion.552 The American Journal of Human Genetics 85, 544–557, NovemThe SCA31 Repeat Insertion Is Located in Newly
Indentiﬁed Introns of BEAN and TK2
According to the NCBI database (build 36.3), the insertion
was located between two genes, BEAN and TK2, and also
upstream of an EST, FLJ27243 (Figure 1). However, we
found previously unidentiﬁed downstream exons for
BEAN and TK2, demonstrating that the insertion is in
introns of these two genes transcribed in opposite direc-
tions (Figure 4). We conﬁrmed by RT-PCR that the
extended versions of BEAN and TK2, which we named71 3 64 52
TK2
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Figure 4. Various Transcripts Spanning the SCA31 Repeat Insertion Site
The locations of BEAN, TK2, FLJ27243, and the SCA31 insertion (red arrowhead) are shown on the physical map of the chromosomal
region between nucleotides 65,000,000 and 65,150,000 on NCBI build 36.3. Exons registered in the NCBI database (shown in a shaded
area) are shown with black boxes, and 50- and 30-UTRs are shown with white boxes attached to them. Although the SCA31 insertion is
located in the intergene region between BEAN and TK2 on the NCBI database, various newly identiﬁed transcripts of these genes (shown
with white boxes with their exon numbers) were detected by RT-PCR, and some of them encompassed the SCA31 insertion. The inser-
tion appeared to be located in introns of BEAN and TK2, two genes transcribed in opposite directions. DA392036 annotated in the NCBI
database seemed to be a part of TK2-EXT. Transcripts 1–3 correspond to the transcripts detected by RT-PCR in Figures 5A and 5B (Table
S1). The primer pairs for RT-PCR are shown with small blue boxes (A–J; Figure 5D and Tables S1 and S2).ber 13, 2009
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Figure 5. Gene Expression of BEAN-EXT, TK2-EXT, and FLJ27243 in Humans
(A) RT-PCR analysis for BEAN-EXT mRNA (transcripts 1 and 2 in Figure 5) showing its brain-speciﬁc expression.
(B) RT-PCR analysis for TK2-EXTmRNA (transcript 3 in Figure 5) showing higher expression in various systemic organs than in the brain.
(C) RT-PCR of FLJ27243mRNA in the human cerebellum. Strand-speciﬁc RT-PCR shows expression of FLJ27243, represented by ‘‘RTwith
AS primer,’’ in the brain. The ‘‘S primer’’ represents transcription in the orientation of BEAN, and ‘‘Random Hexamer’’ indicates tran-
scripts in both directions. The speciﬁcity of this strand-speciﬁc RT-PCR is conﬁrmed by negative ampliﬁcationwhen reverse transcriptase
is omitted [(-)].
(D) Quantitative RT-PCR on BEAN, TK2, FLJ27243, and CKLFmRNAs in controls’ (n ¼ 4) and patients’ (n¼ 2) cerebella. The locations of
RT-PCR primer and probe sets (A–J) are indicated in Figure 5 (C: controls; P: patients; the scale bar represents 1 SD) (see Table S2 for probe
sequences). No consistent difference was found in the expression levels of BEAN (including BEAN-EXT; probe sets: A–G), TK2 (probe sets
H and I), FLJ27243 (probe set J), or CKLF (probe sets K–L) mRNAs compared in the control versus SCA31 patient groups.BEAN-EXT and TK2-EXT, respectively, and FLJ27243 are
all expressed at low levels in the brain (Figures 5A–5C).
Notably, BEAN-EXT, as well as BEAN, is expressed ex-
clusively in the brain. However, neither ordinary nor
quantitative RT-PCR proved that the repeat insertion
caused splicing abnormalities or alterations in the expres-
sion levels of BEAN, TK2, or other nearby genes
(Figure 5D).
The Transcribed SCA31 Insertion Forms Nuclear Foci
in Purkinje Cells
We next performed in situ hybridization to see whether
transcribed repeat sequences form aggregates (‘‘RNA
foci’’) in nuclei, as in RNA-mediated noncoding repeat-
expansion disorders,3 such as DM123 and DM2.27 Using
an LNA probe targeting (UAAAAUAGAA)n, we detected
RNA foci in approximately 30%–50% of the nuclei of
SCA31 patients’ Purkinje cells (Figure 6). Such RNA foci
were never observed in controls, allowing a clear distinc-
tion. This might indicate not only that the insertion is
transcribed as BEAN-EXT transcript in SCA31 brains but
also that the insertion transcribed in the direction ofThe AmericaBEAN-EXT forms abnormal RNA aggregates in Purkinje
cells, the primary target of SCA31. Foci were never
observed with a probe for anti-sense (UUCUAUUUUA)n
repeats corresponding to the TK2-EXT transcripts in either
SCA31 or control brains.
(UGGAA) n, the Disease-Speciﬁc Transcribed
Component of the SCA31 Insertion, binds
to SFRS1 and SFRS9 In Vitro
We next searched for proteins that could potentially bind
to the transcribed SCA31 insertion, particularly to the (UG
GAA)n sequence. Accumulating evidence increasingly
suggests that satellite III (SatIII), the paracentromeric repet-
itive sequences rich in (TGGAA)n, are transcribed under
stress28–30 to form nuclear stress bodies (nSBs) and play
an important role in regulating the splicing machinery
by recruiting certain splicing factors,31 such as serine/argi-
nine-rich splicing factor (SFRS) 1 (also known as ASF/SF2 or
SRp30a) and SFRS9 (SRp30c), to nSBs. On the basis of this
fact, we performed EMSAs and found that SFRS1 and SFRS9
directly bind to (UGGAA)n, the transcribed sequence of
(TGGAA)n, in vitro (Figure 7).n Journal of Human Genetics 85, 544–557, November 13, 2009 553
Figure 6. Presence of RNA Foci in SCA31 Purkinje Cells
RNA foci (red dots) seen in a nucleus (stained with DAPI; blue) of an SCA31 Purkinje cell with an LNA-(TTTTATTCTA)2.5 probe targeting
the transcripts containing the (UAAAAUAGAA)n repeat (autoﬂuorescence; orange). In controls, foci were completely negative. Anti-
sense transcripts, searched with an LNA-(TAGAATAAAA)2.5 probe, did not appear as RNA foci. Scale bars represent 10 mm.(TGGAA)n Is Abundant in Heterochromatin,
Particularly in Centromeric Regions
In order to see the distribution of (TGGAA)n in the human
genome, we also performed an in silico search for
(TGGAA)n and found that these penta-nucleotide repeats
are indeed abundant in the centromeres of chromosomes
2, 4, 7, 10, 16, 17, 20, and Y (Figure 8A). On the other
hand, (TAGAA)n is observed in euchromatins and telo-
meres (Figure 8B). (TAAAATAGAA)n was not detected in
the human genome.
SCA4 and SCA31 Are Not Likely to Be Allelic
Neither the SCA31 insertion nor the single-nucleotide
change in TK2 (AB473217) was detected in SCA4 individ-
uals. PCR-based direct sequencing of all coding exons and
exon-intron boundaries of BEAN, TK2, and FLJ27243 with
40 primer pairs and Southern blot analysis in the genomic
region encompassing BEAN and TK2 were also negative.
These results did not support the hypothesis that SCA4
and SCA31 were allelic diseases. Similarly, the 21 disease
controls13 also did not harbor the insertion. Mutations in554 The American Journal of Human Genetics 85, 544–557, NovemBEAN, TK2, and FLJ27243were not found in the ten disease
controls tested.
Discussion
In summary with regard to the results of our mutation
search, only two genetic changes were found to completely
segregate with the disease: the complex penta-nucleotide
repeat insertion at nucleotide 65,081,803 and a single-
nucleotide change (AB473217) at nucleotide 65,114,245
in human chromosome 16 (NCBI build 36.3). The single-
nucleotide change, located in an intron, did not seem to
have any obvious effects on splicing or expression
patterns, providing no evidence that this is the causative
mutation. On the other hand, the length of the insertion
with penta-nucleotide repeats was inversely correlated
with age of onset, in agreement with the general rules of
repeat-expansion disorders.1–3 We therefore concluded
that the penta-nucleotide repeat insertion containing
(TGGAA)n is the only likely candidate for the SCA31 muta-
tion. The fact that we did not ﬁnd any allelic mutations in(UAAAAUAGAA)4
8
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Figure 7. The Pentanucleotide
(TGGAA)n Binds to Splicing Factors
SFRS1 and SFRS9 In Vitro
EMSA showing speciﬁc binding of SFRS1
isoform 1 (SFRS1-1) (A) and SFRS9 (B) to
RNA oligonucleotide (UGGAA)8. Shifted
bands (arrowheads) were observed in
mixtures of digoxigenin(DIG)-(UGGAA)8
and either GST-SFRS1-1 or GST-SFRS-9.
The shifted bands disappeared with the
addition of nonlabeled (UGGAA)8,
whereas the addition of excess amounts
of nonlabeled (UAGAA)8 or (UAAAAUA-
GAA)4 did not interfere with the band
shift. No shift was seen when DIG-(UG
GAA)8 was mixed with GST alone.ber 13, 2009
BEAN, TK2, or FLJ27243 in our cohort of patients (5 SCA4
and 21 disease-control individuals) does not deny this
conclusion because none of the repeat-expansion diseases,
except SCA6, have allelic mutations.1–3
All the previously known repeat-expansion disorders are
caused by expansions of microsatellites present as polymor-
phic DNA repeats in humans: normal individuals have
smaller numbers of repeats, whereas patients harbor longer
repeats.26 To our knowledge, SCA31 is the ﬁrst human
disease discovered to be associated with a microsatellite
‘‘insertion.’’ The observation in rare controls of shorter in-
serted repeats lacking (TGGAA)n suggests that the inserted
microsatellite has to have sufﬁcient length (R 2.5 kb), the
(TGGAA)n stretch, or both to cause the disease. Notably,
haplotypes based on ﬂanking markers were not similar in
the controls with the rare inserts and the SCA31 patients.
Although this might indicate that the insertions in controls
and SCA31 patients arose from different insertion events,
concluding so is still premature. Both the control and
SCA31 insertshad a preceding 4bpTCACandalsopossessed
(TAGAA)n, (TAAAA)n, and(TAAAATAGAA)n. In fact, controls
with rare premutation alleles in the DM2 repeat were found
to have a haplotype similar to that of DM2 patients.32 Thus,
further analysis will need to address whether SCA31 and
control insertions have different ancestries.
1         2          3         4          5         6          7         8          9        10       11        12       13
 14       15        16       17        18       19        20       21        22        X        Y        MT     Not placed
A TGGAA repeat
1         2          3          4         5          6         7          8         9         10       11        12        13
14       15        16        17       18        19       20        21        22        X        Y        MT      Not placed
B TAGAA repeat
Figure 8. (TGGAA)n Is Particularly Abundant in Centromeric
Regions
(A) (TGGAA)40 sequences are abundant in the centromeres of
chromosomes 2, 4, 7, 10, 16, 17, 20 and Y, whereas they are sparse
in normal euchromosomes.
(B) (TAGAA)40 sequences are widely observed in euchromatin as
well as in telomeres.The AmericaThe presence of (TGGAA)n, the characteristic sequence
of satellites II and III33, suggests that the SCA31 insertion
might be related to heterochromatin; this idea is supported
by our in silico search for (TGGAA)n. SCA31 could be the
second disease associated with heterochromatin insertion
after autosomal-recessive congenital deafness (DFNB10)
(MIM #605316),34 caused by a b-satellite sequence inser-
tion into a coding exon. Although the b-satellite sequence
insertion causes DFNB10 via a loss-of-function mecha-
nism, SCA31 appears to be associated with intronic repeat
insertions that are transcribed to form RNA foci.
How does this insertion cause the disease? Haplo-insufﬁ-
ciency or dominant-negative mechanisms do not appear
likely because both BEAN (including BEAN-EXT) and TK2
(including TK2-EXT) were expressed at the same level in
SCA31 patients’ brains as they were in control brains, at
least at mRNA levels. Paracentromeric satellite sequences
rich in penta-nucleotide repeats (TGGAA)n are thought
to have various essential roles, such as the maintenance of
chromatin conformation.33 The expanded repeat sequence
of (TGGAA)n, which tends to take non-B DNA structures,
33
might induce local chromosomal structural changes that
could alter the expressions of other genes, as proposed in
FRDA caused by (GAA)n expansion (‘‘sticky DNA’’).
1
Alternatively, there is a possibility that the transcripts of
the repeat insertion convey the pathogenesis (i.e., ‘‘RNA-
mediated gain-of-function mechanism’’).3 Earlier onset in
homozygotes than in heterozygotes, as described in a
previous study14, appear to support the gain-of-function
mechanism. In noncoding repeat expansion disorders,
such as DM123, DM227, FXTAS35, HDL236, and SCA822,
transcribed repeats form aggregates (‘‘RNA foci’’) in the
nuclei of affected cells. The sequestration of proteins
that bind to these foci, such as muscleblind-like protein
1 andCUG-binding protein (CUG-BP)13 in DM1 andDM2,
as well as CUG-BP1 and heterogeneous nuclear ribonu-
cleoprotein (hnRNP)A2 in FXTAS37, are believed to cause
dysregulation of alternative splicing. In light of these facts,
the presence of nuclear RNA foci in Purkinje cells and
in vitro binding of essential splicing factors SFRS1 and
SFRS9 to (UGGAA)n imply that SCA31 might also be asso-
ciated with RNA-mediated gain-of-function mechanisms.
SR proteins, such as SFRS1, play important roles in
constitutive splicing, alternative splicing regulation in
which they antagonize hnRNPs31,38, and stabilizing
mRNAs.38 Suppression of SFRS1 expression results in
embryonic lethality in C. elegans39 and death in particular
subsets of neurons.40 If the transcripts of the SCA31 inser-
tion should indeed sequester SFRS1 and SFRS9 by forming
RNA foci, it might disturb the pre-mRNA processing
patterns of various genes41 and ultimately lead to neuronal
death. Interestingly, overexpression of hsru, the Drosophila
noncoding RNA gene similar to SatIII, is shown to exacer-
bate neurodegeneration in a ﬂy model of polyglutamine
disease, in which sequestration of transcription factors
such as CREB binding protein (CBP) are considered impor-
tant for pathogenesis.42 Further analysis is clearly needed,n Journal of Human Genetics 85, 544–557, November 13, 2009 555
not only to dissect how this newly indentiﬁed insertion
mutation causes a human disease, but also to disclose the
roles of highly repeated sequences in heterochromatin.
Supplemental Data
Supplemental Data include four tables and can be found with this
article online at http://www.cell.com/AJHG.
Acknowledgments
Wewould like to thank the families who participated in this study,
as well as Iku Sudo, Minori Kono, and Hideko Uno for their tech-
nical assistance. This study was funded by numerous grants,
particularly from the Health and Labour Sciences Research Grants
on Human Genome (KI) and Ataxic Diseases (HM), Ministry of
Health, Labour and Welfare, Japan, and the 21st Century COE
Program, Brain Integration and its Disorders, the Ministry of
Education, Science and Culture, Japan (HM). We also thank Laura
P.W. Ranum (University of Minnesota) and Christopher E. Pearson
(Hospital for Sick Children, Toronto) for their advice. We thank
Eric Sheldon (Scientiﬁc Language Editing Team, Tsukuba, Japan)
for proofreading our manuscript.
Received: May 19, 2009
Revised: August 25, 2009
Accepted: September 21, 2009
Published online: October 29, 2009
Web Resources
The URLs for data presented herein are as follows:
BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi
dbSNP, http://www.ncbi.nlm.nih.gov/SNP/
DDBJ, http://www.ddbj.nig.ac.jp/
ESEﬁnder 3.0, http://rulai.cshl.edu/cgi-bin/tools/ESE3/eseﬁnder.
cgi?process¼home
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.
nlm.nih.gov/sites/entrez?db¼OMIM
NCBI, http://www.ncbi.nlm.nih.gov/
Accession Numbers
TheGenBank accession numbers forHomo sapiens BEAN-EXT tran-
scripts are AB472390 (#1 in Figure 5), AB472391 (#2), AB472392
(#3), AB47233 (#6), AB472395 (#7), AB472396 (#4), AB472398
(#8), and AB472399 (#5). The GenBank accession number for
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